

OmniGene Bioproducts, Inc.

OmniGene Bioproducts, Inc. Institutional Biosafety Committee Minutes of March 25, 2003 Meeting

Present: David Form, Debbie Knight, Lin Howitt, Rogers Yocum (IBC chairman)

Absent: Scott Van Arsdell

Minutes:

The meeting was called to order at 4:15 PM, Tuesday, March 25, 2003. The primary agenda item was to review the current ongoing recombinant DNA projects at OmniGene Bioproducts, Inc. Rogers Yocum gave a general scientific review of the projects and discussed the containment levels required for the projects, which are BL-1 or exempt. Only three projects are currently active, Project #510, which constitutes the major activity of the company, Project #512, a minor activity of the company, and Project #590.2, which involves occasional wholesaling of a harmless research enzyme.

There have been no new projects started since the last IBC, but it is anticipated that a new project involving only exempt experiments in a food grade bacterium will begin in the next year. Since the project will involve only exempt experiments, prior approval of the IBC is not required. If the project is actually started, it will be reviewed in more detail at the next IBC meeting.

A brief review was then given of the list of all recombinant DNA projects on hold at OmniGene Bioproducts, Inc. Most projects are on hold, with materials from those projects still being stored in freezers on site.

Since Scott Van Arsdell was unable to attend, written handouts for this meeting will be mailed to Scott Van Arsdell for his review.

If you approve of the minutes as they stand, please sign on the line below, and return to Rogers Yocum. If you would like to request an amendment, please write your proposed amendment on this copy and return it. Thanks.

Debbie Knight Date: 3/25/03

1. The first part of the document is a header section containing the following information:

2. The second part of the document is a list of items, each with a corresponding number and a brief description:

3. The third part of the document is a list of items, each with a corresponding number and a brief description:

4. The fourth part of the document is a list of items, each with a corresponding number and a brief description:

5. The fifth part of the document is a list of items, each with a corresponding number and a brief description:

6. The sixth part of the document is a list of items, each with a corresponding number and a brief description:

7. The seventh part of the document is a list of items, each with a corresponding number and a brief description:

8. The eighth part of the document is a list of items, each with a corresponding number and a brief description:

OmniGene Bioproducts, Inc.

OmniGene Bioproducts, Inc. Institutional Biosafety Committee Minutes of March 2, 2004 Meeting

Present: David Form, Debbie Knight, Lin Howitt, Rogers Yocum (IBC chairman)

Missing: Scott Van Arsdell

Minutes:

The meeting was called to order at 4:15 PM, Tuesday, March 2, 2004. The primary agenda item was to review the current ongoing recombinant DNA projects at OmniGene Bioproducts, Inc., and to approve one new project, #513, that was started in June, 2003. Rog Yocum gave a general scientific review of the project and discussed the containment levels required for experiments under the project, all of which are exempt or BL1. Only two projects are currently active, the new Project #513, which now constitutes the major activity of the company, and Project #590.2, which involves occasional wholesaling of a harmless research enzyme. The two other projects that were active as of the last IBC meeting, project #510 and project #512, (March 25, 2003) are now on hold.

If you approve of the minutes as they stand, please sign on the line below, and return to Rog Yocum. If you would like to request an amendment, please write your proposed amendment on this copy and return it. Thanks.

Debbie J. Knight Date: 3/2/04

DECLASSIFICATION AUTHORITY
50 CFR 17.104 (a) (1) - (3)
50 CFR 17.104 (b) (1) - (3)

Authority: 50 CFR 17.104 (a) (1) - (3)
50 CFR 17.104 (b) (1) - (3)

DECLASSIFIED BY: [illegible]
DATE: [illegible]

DECLASSIFICATION AUTHORITY: 50 CFR 17.104 (a) (1) - (3)
50 CFR 17.104 (b) (1) - (3)

[Signature]
[illegible]

OmniGene Bioproducts, Inc.

OmniGene Bioproducts, Inc. Institutional Biosafety Committee Minutes of April 27, 2005 Meeting

Present: ~~David Form~~, Debbie Knight, Scott Van Arsdell, Lin Howitt, Rogers Yocum (IBC chairman)

Minutes:

The meeting was called to order at 4:15 PM, Wednesday, April 27, 2005. The primary agenda items were 1) to review the current ongoing recombinant DNA projects at OmniGene Bioproducts, Inc., 2) to approve one new staff member who recently joined Project #513, and 3) to have each member of the IBC fill out a biographical sketch to submit to the NIH. Rog Yocum gave a brief general scientific review of the project and discussed the containment levels required for experiments under the project, all of which are exempt or BL1. Only two projects are currently active, Project #513, Amino Acid Production #2, which still constitutes the major activity of the company, and Project #590.2, which involves occasional wholesaling of a harmless research enzyme. All other past projects are now on hold.

If you approve of the minutes as they stand, please sign on the line below, and return to Rog Yocum. If you would like to request an amendment, please write your proposed amendment on this copy and return it. Thanks.

Debbie Knight Date: 4/27/05